Analysis
Sling Therapeutics closed a $123 million Series C financing led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management, to fund continued Phase 3 development of linsitinib, an oral small-molecule treatment for thyroid eye disease, according to BioSpace and Fierce Biotech.
The Science And The Trial
Sling is a clinical-stage biopharmaceutical company developing linsitinib, an oral IGF-1R (insulin-like growth factor 1 receptor) inhibitor, for thyroid eye disease -- an autoimmune condition that causes eye bulging, double vision and, in severe cases, vision loss. The company has commenced a global Phase 3 pivotal trial called ORBIT, evaluating linsitinib in adults with moderate to severe active thyroid eye disease. Linsitinib has been granted U.S. Fast Track Designation, a status intended to speed FDA review of drugs addressing serious conditions with unmet medical need.
“The company has commenced a global Phase 3 pivotal trial called ORBIT, evaluating linsitinib in adults with moderate to severe active thyroid eye disease.”
Why Oral Matters Here
The current standard of care for thyroid eye disease is Amgen's Tepezza (teprotumumab), an IV-infused IGF-1R inhibitor that requires repeated hospital or clinic visits over several months. Sling's pitch is that an oral, small-molecule version of a similar mechanism could offer comparable efficacy with dramatically better convenience -- patients could take a pill rather than schedule recurring infusions, a meaningful quality-of-life difference for a chronic autoimmune condition.
Competitive Landscape
- Amgen's Tepezza -- the dominant approved therapy and Sling's direct commercial target; Tepezza's sales have run into the hundreds of millions annually, proving out the market even as patients cite the infusion burden as a drawback.
- Viridian Therapeutics -- developing its own IGF-1R-targeted therapies for thyroid eye disease, including both an IV and a subcutaneous formulation, making it the closest clinical-stage competitor racing toward market.
- Roche/Genentech and other large pharma -- have shown interest in the thyroid eye disease category more broadly given Tepezza's commercial proof point, raising the possibility of acquisition interest for whichever challenger asset reads out strongest Phase 3 data.
The Numbers In Context
A $123 million Series C to fund a global Phase 3 trial is a substantial but not unusually large biotech round by 2026 standards -- comparable in scale to AusperBio's $120 million Series C for its hepatitis B program, another late-stage asset heading toward commercialization readiness.
What To Watch
Phase 3 trials are where biotech theses are made or broken, and linsitinib's oral convenience advantage only matters commercially if its efficacy and safety data end up comparable to Tepezza's -- an IV drug that works better, even if less conveniently, still wins on physician preference. Investors underwriting this round are betting on a data readout that has not happened yet; the ORBIT trial's timeline to topline results was not disclosed in the financing announcement, leaving the actual proof point still ahead.